NEW YORK (GenomeWeb News) — Promega has expanded its equity stake in Aussie RNAi company Benitec by buying 1.8 million ordinary shares at AU$.105 apiece ($.09), or $158,000, Benitec said today.
 
The deal, which is a 20-percent discount from the average trading price of Benitec shares over the past 60 days, follows the conversion of a year-old promissory note and increases Promega’s stake in the Australian company to 6.15 percent.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.